|
|
-
Hyperion Therapeutics Acquires Worldwide Rights To BUPHENYL
6/3/2013
|
-
Hyperion Therapeutics Posts Q1 Net Loss Of $9.0 Mln Or $0.52/Share Vs. Loss $11.9 Mln Or $25.33/Share Last Year
5/9/2013
|
|
|
-
Hyperion Therapeutics Exercises Option To Acquire Rights To BUPHENYL(R) And AMMONUL(R)
5/2/2013
|
-
Hyperion Therapeutics Receives Orphan Drug Exclusivity From FDA
5/2/2013
|
-
Hyperion Therapeutics Issued Key Patent Pertaining To Use Of Fasting Ammonia
4/16/2013
|
-
Hyperion Therapeutics Completes Follow-On Offering And Announces Exercise Of Underwriters' Over-Allotment Option
3/13/2013
|
|
|
-
Hyperion Therapeutics Announces Pricing Of Follow-On Offering
3/8/2013
|